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Abstract
Introduction Mesalamine (5-aminosalicylic acid; 5-ASA)
is recommended first-line therapy for mild-to-moderate
ulcerative colitis. Many mesalamine formulations employ a
pH-dependent release mechanism designed to maximize
drug release in the colon. This study compared the in vitro
release of 5-ASA from six commercially available mesa-
lamine formulations at pH levels similar to those typically
encountered in the human gastrointestinal tract.
Methods The release of 5-ASA from six mesalamine
formulations [Mesalazin-Kohlpharma (Kohlpharma, Ger-
many), Mesalazin-Eurim (Eurimpharm, Germany),
Mesalazina-Faes (Faes Farma, Spain), Mesalazine EC
(Actavis B.V., Netherlands), Mesalazine EC 500 PCH
(Pharmachemie B.V., Netherlands); multimatrix mesala-
mine (Shire US Inc., USA)] was monitored separately at
three different pH levels [1.0 (2 h), 6.4 (1 h), and 7.2 (8 h)]
using United States Pharmacopeia dissolution apparatus II.
The dissolution percentage was calculated as a mean of 12
units for each formulation.
Results At pH 1.0 and 6.4,\1 % of 5-ASA release was
observed for each of the mesalamine formulations tested.
At pH 7.2, complete release of 5-ASA occurred within 1 h
for Mesalazine EC and Mesalazine EC 500 PCH, and
within 2 h for Mesalazin-Kohlpharma, Mesalazin-Eurim,
and Mesalazina-Faes; complete release of 5-ASA from
multimatrix mesalamine occurred within 7 h. Little vari-
ability in rate of 5-ASA dissolution was observed between
tablets of each formulation.
Conclusion At pH 7.2, 5-ASA release profiles were
variable among the commercially available mesalamine
formulations that were tested.
Key Points
This study examined mesalamine (5-aminosalicylic
acid; 5-ASA) release from six commercially
available mesalamine formulations in simulated
physiological pH conditions.
At pH 1.0 and pH 6.4,\1 % 5-ASA release was
observed for each of the mesalamine formulations
tested.
At pH 7.2, 5-ASA was completely released within
1 h for Mesalazine EC and Mesalazine EC 500 PCH,
and within 2 h for Mesalazin-Kohlpharma,
Mesalazin-Eurim, and Mesalazina-Faes; complete
release of 5-ASA from multimatrix mesalamine
occurred within 7 h.
1 Introduction
Ulcerative colitis (UC), a chronic mucosal inflammatory
condition that affects the colon and rectum, is charac-
terized by symptoms of abdominal pain, diarrhea, and
rectal bleeding, and is typically diagnosed through
endoscopic biopsy [1]. Mesalamine (5-aminosalicylic
acid; 5-ASA) is a topical, anti-inflammatory compound
that acts locally within the colonic mucosa to reduce
inflammation, and is recommended first-line treatment
for patients with active mild-to-moderate UC [2]. While
both oral and rectal formulations of 5-ASA are available
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to patients, rectal formulations are associated with leak-
age and abdominal bloating, and patient compliance to
prescribed dosing regimens of rectal formulations
remains poor [3]. Consequently, oral formulations of
5-ASA have become the mainstay treatment option for
mild-to-moderate UC [3].
When mesalamine is administered orally via an
unprotected delivery system, the active drug is quickly
absorbed in the upper gastrointestinal (GI) tract, resulting
in the systemically absorbed drug having little clinical
effect [4, 5]. In order to achieve stable delivery of
5-ASA to the mucosa of the terminal ileum and colon,
numerous formulations have been developed that aim to
delay the release of the active drug during passage
through the GI tract. For example, protective enteric
coatings are used in some mesalamine formulations to
control or delay the release of the active drug [4, 6–9].
In particular, many of these mesalamine formulations use
a pH-dependent release mechanism designed to minimize
active drug release at acidic pH levels, such as those
observed higher in the digestive tract (e.g., pH *2 in
the stomach and pH *6 in the small intestine), and
maximize drug release at more basic pH levels, such as
those observed in the colon (pH 7–8) [10]. The colonic
pH in patients diagnosed with UC has been observed at
levels lower than pH 7 due to reduced mucosal bicar-
bonate secretion, increased mucosal and bacterial lactate
production, and impaired short-chain fatty acid absorp-
tion and metabolism [11, 12].
The objective of the study was to compare the in vitro
dissolution profiles of mesalamine from commercially
available products in Europe indicated for the treatment
of UC. The mesalamine formulations included in this set
of dissolution experiments were selected based upon two
criteria: (1) They were among the most widely clinically
used mesalamine formulations in Europe at the time of
the study (IMS Health Monthly MIDAS Data, October
2012); and (2) With the exception of multimatrix
mesalamine, the selected formulations had not been
included in an initial set of dissolution experiments
conducted by our laboratory [13]. This in vitro study
compared 5-ASA release at physiologically relevant pH
conditions from the following commercially available,
controlled-release mesalamine formulations: Mesalazin-
Kohlpharma (Kohlpharma, Germany), Mesalazin-Eurim
(Eurimpharm, Germany), Mesalazina-Faes (Faes Farma,
Spain), Mesalazine EC (Actavis B.V., Netherlands),
Mesalazine EC 500 PCH (Pharmachemie B.V., Nether-
lands), and multimatrix mesalamine (Shire US Inc.,
Wayne, PA, USA).
2 Methods
Dissolution experiments were conducted with the follow-
ing mesalamine formulations: Mesalazin-Kohlpharma
500 mg tablets, Mesalazin-Eurim 500 mg tablets,
Mesalazina-Faes 500 mg tablets, Mesalazine EC 500 mg
tablets, Mesalazine EC 500 PCH 500 mg tablets, and
multimatrix mesalamine 1.2 g tablets. United States Phar-
macopeia (USP) apparatus II (paddle) was used for the
dissolution study (Sotax AT7TM dissolution tester; Sotax
Corporation, Horsham, PA, USA) [14].
In order to investigate the effect of simulated GI con-
ditions on the release of active 5-ASA, dissolution testing
was performed in an experiment across different physio-
logically relevant pH levels. Tablets of each formulation
were individually exposed to the dissolution medium in an
acid stage (pH 1.0) for 2 h, an initial buffer stage (pH 6.4)
for an additional hour, and in a subsequent buffer stage (pH
7.2) for 8 h, simulating anticipated pH environments to be
encountered after ingestion in the stomach, small intestine,
and colon, respectively (Table 1) [12]. The composition of
the dissolution media used during each stage is listed
below.
• Acid stage pH 1.0 (0.1 N HCl): dilution of hydrochloric
acid 37 % with purified water.
• Phosphate buffer pH 6.4 (0.2 M Na3PO4): 0.2 M
Na3PO4 solution with 0.1 N HCl (if needed, pH
adjusted with 2 N NaOH or 2 N HCl).
• Phosphate buffer pH 7.2 (0.2 M Na3PO4): pH 6.4
buffer with 2 N NaOH (if needed, pH was adjusted
with 2 N NaOH or 2 N HCl).
Sink conditions were maintained. The solubility of
mesalamine in phosphate buffers at pH 6.0 and 7.2 was
approximately 1.2–5.5 mg/mL, respectively. Buffer
capacity has been evaluated according to USP as the
quantity of acid or base needed to change the buffer pH
expressed as Eq/L per unit pH. The buffer capacity at pH
6.4 in our study was 0.02 Eq/L per unit pH for either
addition of 1 N HCl or 1 N NaOH; at pH 7.2, the buffer
capacity was 0.02 Eq/L per unit pH for addition of 1 N
HCl and 0.01 Eq/L per unit pH for addition of 1 N NaOH.
A paddle speed of 100 rpm was selected to ensure adequate
mixing as well as completion of dissolution in a reasonable
time period.
The dissolution bath was maintained at a mean [±s-
tandard deviation (SD)] temperature of 37 C (±0.5), and
the quantitative determination of 5-ASA released was
measured by ultraviolet-visible (UV-Vis) spectrophotom-
etry at wavelengths of 301 nm at pH 1.0, and 330 nm for
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both pH 6.4 and 7.2 (PerkinElmer Lambda 25TM; Perk-
inElmer Life and Analytical Sciences, Inc., Waltham, MA,
USA). The dissolution percentage was calculated as a mean
of 12 units for each formulation.
3 Results
In the acid stage and first buffer stage,\1 % of 5-ASA
combined release was observed for each of the mesalamine
formulations tested. However, some variability in 5-ASA
dissolution profiles was observed between the mesalamine
formulations at buffer stage 2 (pH 7.2), after the initial
exposure to pH 1.0 for 2 h and pH 6.4 for 1 h (Fig. 1).
Mesalazine EC and Mesalazine EC 500 PCH demonstrated
complete release of 5-ASA within 1 h at pH 7.2, while
Mesalazin-Kohlpharma, Mesalazin-Eurim, and Mesalaz-
ina-Faes exhibited complete release within 2 h. Multima-
trix mesalamine demonstrated complete 5-ASA release
over a period of 7 h (Fig. 1). Analysis of the pill-to-pill
variability in mesalamine tablet dissolution within each
formulation revealed minimal variability between tablets
(Table 2).
4 Discussion
This study evaluated the 5-ASA dissolution profiles of
various mesalamine formulations across different pH
levels. In order to delay the release of 5-ASA until the drug
reaches the colonic mucosa, many mesalamine formula-
tions employ pH-dependent release mechanisms that limit
drug release in acidic environments [10]. As expected, all
mesalamine formulations tested in our study released little
to no drug at acidic pH conditions. However, at pH 7.2,
some variability in the dissolution profiles of mesalamine
formulations was observed. Mesalazin-Kohlpharma,
Mesalazin-Eurim, Mesalazina-Faes, Mesalazine EC, and
Mesalazine EC 500 PCH released 5-ASA within 1 or 2 h,
while multimatrix mesalamine released the active drug
within 7 h. Results for multimatrix mesalamine were
consistent with previous observations of 5-ASA release
from multimatrix mesalamine under similar conditions [6,
13, 15, 16].
A recently published study by Goyanes et al. [17] also
examined the dissolution profiles of several commercially
available mesalamine formulations. In this study, a novel
technology, the Auto pH SystemTM, was used to mimic
human GI parameters in vitro, including pH, ionic strength,
and buffer capacity. The system allowed for dissolution
testing at seven different pH conditions from 5.6 to 7.4. A
bicarbonate-based buffer was also used, which more clo-
sely resembled the ionic composition and buffer capacity
of in vivo intestinal fluids, compared with the phosphate
buffer used in the current experiment. As the methods used
in the Goyanes study were substantially different, it is
difficult to directly compare their results to those of the
current study. The Goyanes et al. study, nevertheless, also
demonstrated that different commercial mesalamine for-
mulations showed different release profiles and could also
be attributed at least partially to a pH-dependent release
mechanism.
A prior study by Fadda et al. [18] demonstrated that
dissolution results from the same mesalamine formulation
may vary depending on the type of buffer used. In that
study, multimatrix mesalamine was exposed to pH 1.2
(0.1 M HCl) for 2 h, then transferred to pH 7.4 in either a
Table 1 Experimental
conditions for the study of
5-ASA release from
mesalamine tablets (USP II
method)
Conditions Acid stage Buffer stage 1 Buffer stage 2
Dissolution media 750 mL, 0.1 N HCl 950 mL, 0.16 M
phosphate buffer
960 mL, 0.16 M
phosphate buffer
pH 1 6.4 7.2
Duration (h) 2 1 8
Sample time (h) 2 1 1
Rotation speed (rpm) 100 100 100
5-ASA 5-aminosalicylic acid, USP United States Pharmacopeia



















Mesalazine EC Mesalazine EC 500 PCH Multimatrix mesalamine
Fig. 1 Release of 5-ASA from mesalamine formulations at pH 7.2
over 8 h
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phosphate buffer or Krebs bicarbonate buffer. In the
phosphate buffer, the zero-order, slow drug release was
observed, and the drug started to release after about 30 min
at pH 7.4, reaching\80 % release after 9 h. In the bicar-
bonate buffer, both the lag times and drug release profiles
were different from the phosphate buffer. The zero-order,
slow drug release was no longer apparent, and the drug
started to release approximately 3 h after exposure to pH
7.4, reaching 90–100 % release after 8 h. Drug release in
both media suggested release of 5-ASA over many hours.
Our study also exposed mesalamine formulations to an
intermediary buffer stage of pH 6.4 for 1 h prior to
exposure at pH 7.2.
While different formulations of mesalamine may reveal
variations in dissolution rates in vitro, it remains to be
determined if these differences correlate with 5-ASA
delivery at the colon. Additionally, while physiologically
relevant pH conditions were used in our study, the phos-
phate buffer used may not be physiologically relevant,
limiting the ability to correlate results with in vivo per-
formance [18]. Further studies will be needed to determine
if the findings of our study, as well as those of other dis-
solution studies, are clinically relevant.
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